iBio, Inc. (IBIO)
1.42
-0.01
(-0.70%)
USD |
NASDAQ |
Aug 24, 16:00
1.41
-0.01
(-0.70%)
After-Hours: 07:19
iBio Enterprise Value : -23.42M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | -23.42M |
| August 21, 2026 | -23.07M |
| August 20, 2026 | -21.69M |
| August 19, 2026 | -21.00M |
| August 18, 2026 | -22.38M |
| August 17, 2026 | -22.38M |
| August 14, 2026 | -23.07M |
| August 13, 2026 | -24.11M |
| August 12, 2026 | -21.69M |
| August 11, 2026 | -21.69M |
| August 10, 2026 | -24.11M |
| August 07, 2026 | -23.77M |
| August 06, 2026 | -24.46M |
| August 05, 2026 | -24.11M |
| August 04, 2026 | -22.04M |
| August 03, 2026 | -23.42M |
| July 31, 2026 | -24.11M |
| July 30, 2026 | -24.46M |
| July 29, 2026 | -25.49M |
| July 28, 2026 | -24.46M |
| July 27, 2026 | -22.38M |
| July 24, 2026 | -23.07M |
| July 23, 2026 | -24.11M |
| July 22, 2026 | -24.80M |
| July 21, 2026 | -23.77M |
| Date | Value |
|---|---|
| July 20, 2026 | -25.15M |
| July 17, 2026 | -24.80M |
| July 16, 2026 | -25.84M |
| July 15, 2026 | -23.07M |
| July 14, 2026 | -22.73M |
| July 13, 2026 | -22.38M |
| July 10, 2026 | -20.31M |
| July 09, 2026 | -20.31M |
| July 08, 2026 | -19.97M |
| July 07, 2026 | -17.55M |
| July 06, 2026 | -16.51M |
| July 02, 2026 | -14.44M |
| July 01, 2026 | -12.02M |
| June 30, 2026 | -12.02M |
| June 29, 2026 | -12.71M |
| June 26, 2026 | -14.78M |
| June 25, 2026 | -17.55M |
| June 24, 2026 | -16.51M |
| June 23, 2026 | -15.48M |
| June 22, 2026 | -12.37M |
| June 18, 2026 | -14.09M |
| June 17, 2026 | -17.20M |
| June 16, 2026 | -18.93M |
| June 15, 2026 | -15.48M |
| June 12, 2026 | -14.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Capricor Therapeutics, Inc. | 248.25M |
| Ocugen, Inc. | 449.04M |
| CytomX Therapeutics, Inc. | 391.40M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.73M |
| Total Expenses (Quarterly) | 7.73M |
| EPS Diluted (Quarterly) | -0.0646 |
| Earnings Yield | -40.68% |
| Normalized Earnings Yield | -38.41 |